Practical Treatment Choices and Emerging Therapies for Urticaria

Conclusions

• Chronic spontaneous urticaria now has multiple therapeutic options, but treatment choice should be guided by disease speed, age, comorbid type 2 inflammation, and safety considerations rather than by a single one-size-fits-all approach.
• Omalizumab remains a well-established and highly effective option with a strong safety record, but it is less useful in some IgE-independent or more refractory endotypes and may lose efficacy in some patients over time.
• Dupilumab appears especially valuable for patients with type 2 comorbidities and has a favorable safety profile, but its onset is slower than newer options and it may not be ideal when rapid symptom control is urgently needed.
• Remibrutinib offers very rapid control of hives and angioedema and is attractive as an oral option, but its twice-daily dosing, adult-only status, interaction profile, and long-term safety uncertainty limit how broadly it can be used.
• Early real-world experience suggests remibrutinib’s bleeding concerns may be more visually apparent than clinically dangerous, though patients still need counseling and perioperative precautions.
• Head-to-head comparisons between remibrutinib and dupilumab are important because the key tradeoff is likely speed versus durability and broader type 2 benefit.
• The urticaria pipeline is expanding quickly across multiple mechanisms, including enhanced anti-IgE strategies, BTK inhibitors, KIT inhibitors, JAK inhibitors, and MRGPRX2 antagonists.
• Future KIT-directed therapies may be extremely potent because they deplete mast cells, but they may also carry meaningful on-target effects such as hair and pigment changes and possible reproductive concerns.
• BTK-targeted approaches may vary by binding mode and durability, and protein-degrading strategies could improve efficacy but may also intensify adverse effects.
• MRGPRX2 and other novel targets suggest that urticaria is mechanistically heterogeneous, and the field is moving toward endotype-driven treatment selection and prediction of which patient will respond to which drug.